ArticleWorld journal of gastrointestinal oncology2025
Evaluation and prediction of Ki-67 expression in hepatocellular carcinoma.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanistic investigation of the hepatotoxicity and potential carcinogenicity of microcystin-LR, -LA, and -RR in the HepaRG cell line model.Archives of toxicology · 2026Article
- Integrated multi-omic analyses reveal novel gene-metabolite relationships in human steatohepatitic hepatocellular carcinoma.Journal of lipid research · 2026Article
- Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis.Radiology and oncology · 2026Article
- Predictive Efficacy of a Combined Triphasic CT Radiomics and Clinical Feature Model for Ki-67 Expression in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver with hepatocellular differentiation. The diagnosis and prognosis of HCC are significantly influenced by tumor markers. Ki-67 as an immunohistochemical marker is a nuclear antigen related to the level of cell proliferation activity. Ki-67 is an important prognostic markers of HCC. In order to help clinicians assess patient outcomes, Ki67 can function as an independent prognostic indicator. In HCC, elevated Ki67 expression is linked to a worse prognosis and a higher chance of recurrence. It is considered a significant marker of clinical, histopathological, and immunological status and prognosis in HCC. Preoperative evaluation and prediction of Ki-67 expression in HCC with machine learning models based on intratumoral and peritumoral radiomic features now have a significant role in patient management and care and will provide a more definite direction for subsequent research. This article aims to evaluate the role of Ki-67 and various other biomarkers in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.